Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]
- To study the effects of recurrence and progression on health-related quality of life
- To study the effects of repeat cystoscopy on HRQL.
- To study the patients' assessments of a hypothetical prognostic model and how this
affects their preference for the mode of surveillance.
OUTLINE: This is a multicenter study.
Quality-of-life questionnaires developed by the European Organization for Research and
Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to
non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to
muscle-invasive bladder cancer will be combined and used in conjunction with the general
cancer questionnaire QLQ-C30.
Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients.
Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first
routine follow-up and annually until the end of study.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Quality of life as measured by EORTC QLQ-C30, QLQ-BLS24, and QLQ-BLM30 questionnaires
Maurice Zeegers, MD
University of Birmingham